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 A new series of isoxazole derivatives, N-phenyl-5-carboxamidyl isoxazoles, was investigated for their 
anticancer activity with solid tumor selectivity. Six N-phenyl-5-carboxamidylisoxazoles were chemically 
synthesized and evaluated by the in vitro disk-diffusion assay and IC50 cytotoxicity determination. The 
results showed that one of the derivatives, compound 3, N-(4-chlorophenyl)-5-carboxamidyl isoxazole, was 
the most active against colon 38 and CT-26 mouse colon tumor cells with an IC50 of 2.5 µg/mL for both cell 
lines. Western blot analysis showed that compound 3 significantly down-regulated the expression of 
phosphorylated STAT3 in both human and mouse colon cancer cells indicating that the mechanism of action 
for compound 3 may involve the inhibition of JAK3/STAT3 signaling pathways. Flow cytometric analysis 
with Annexin V staining showed that the death induced by compound 3 is mediated through cell necrosis and 
not apoptotic pathway. In summary, our results show that compound 3 is a new N-phenyl-5-carboxamidyl 
isoxazole with potential anticancer activity. Compound 3 inhibits the phosphorylation of STAT3, a novel 
target for chemotherapeutic drugs, and is worthy of further investigation as a potential chemotherapeutic 
agent for treating colon cancer. 
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1.  Introduction 
 
Isoxazole and some naturally occurring 
isoxazole derivatives are small molecules with 
interesting biological activities (Figure 1). For 
example, ibotenic acid derived from the 
mushroom Amanita muscaria is a potent 
neurotoxin [1]. Ibotenic has been shown to be 
highly neurotoxic when injected directly into the 
brains of mice and rats [2, 3]. It has been reported 
that ibotenic acid can cross the blood brain barrier 
unchanged, yet some may be metabolized into 
another isoxazole derivative, muscimol, in the 
process (Figure 2) [4, 5]. Muscimol is also 
produced naturally in the mushrooms Amanita 
muscaria [3]. It is commonly used in biomedical 
research as an agonist of γ-aminobutyric acid A 
receptor (GABAAR). The ligand, γ-aminobutyric 
acid A (GABA), is the primary inhibitory 
neurotransmitter that plays a role in regulating 
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Figure 1.  Structures of isoxazole and some of its derivatives 
 
 
Isoxazole forms the basis for several drugs 
such as leflunomide (a disease-modifying 
antirheumatic drug, DMARD), valdecoxib (a 
COX-2 inhibitor), and zonisamide (an anti-
convulsant) (Figure 1). Two series of isoxazole 
derivatives (N-phenyl-4-carboxamidyl and N-
phenyl-3-carboxamidyl isoxazoles) are associated 
with important biological activities in different 
therapeutic areas. A well known DMARD, 
leflunomide, is an N-phenyl-4-carboxamidyl 
isoxazole. The active metabolite of leflunomide, 
A771726 is known to inhibit TNF- and IL-1α 
from Kupffer cells in vitro [6]. In addition, 
leflunomide has been shown to inhibit the 
production of TNF-, IL-1α and IL-6 induced by 
bacterial lipopolysaccharides (LPS) in peritoneal 
macrophages in rats with adjuvant arthritis [7]. 
Our previous synthetic and biological studies 
showed that N-(4-chlorophenyl)-3-carboxamidyl-
5-methylisoxazole is a TNF- inhibitor [8]. We 
also showed that a number of N-(substituted-
phenyl)-3-carboxamidyl-5-methylisoxazoles acted 
as anti-inflammatory agents in vivo [9, 10]. Based 
on the intriguing biological activities of both N-
phenyl-4-carboxamidyl and N-phenyl-3-
carboxamidyl isoxazoles, we hypothesized that the 
new series of isoxazoles, N-phenyl-5-
carboxamidyl isoxazoles, may possess potent 
biological activity. As a preliminary investigation 
for this new series of isoxazoles, we synthesized 
six N-phenyl-5-carboxamidyl isoxazoles (Figure 
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2) and investigated these compounds for their 
anticancer activity using mouse colon carcinoma 
cells. In addition, a preliminary mechanistic study 
was carried out in mouse colon 38 cells that 
constitutively express activated Akt kinase and 
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Figure 2.  Structures of the six N-phenyl-5-carboxamidylisoxazoles under investigation  
 
 
2. Materials and Methods 
 
2.1 Chemicals and Materials 
Recombinant Human EGF was purchased 
from PeproTech (Rocky Hill, NJ). Antibodies 
against phospho-STAT3 (tyr705), phospho-Akt 
(ser473) and Akt were obtained from Cell 
Signaling Technology (Danvers, MA). Antibody 
against actin was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). Bovine calf 
serum was purchased from HyClone Laboratories 
(Logan, UT). Bicinchoninic acid protein (BCA) 
assay kit and SuperSignal West Pico 
chemiluminescence substrate system were 
purchased from Pierce (Rockford, IL). Cocktail 
protease inhibitors (AEBSF 500 μM) were 
purchased from EMD4Biosciences (San Diego, 
CA). All other chemicals used in synthesis and 
biological studies were purchased from Sigma-
Aldrich (St. Louis, MO) unless otherwise 
specified. 
 
2.2 Cell Lines 
The mouse colon 38 tumor cells were 
maintained in Dulbecco's Modification of Eagle's 
Medium/Ham's F12, 50/50 Mix (DMEM/F12) 
(MediaTech, Manassas, VA) containing 2% 
bovine calf serum, 2 mM L-glutamine, penicillin 
(100 U/mL) and streptomycin (100 µg/mL), 10 
ng/mL recombinant human-EGF, 1 % insulin-
transferrin-selenium-A (ITS-A) solution 
(Invitrogen, Carlsbad, CA) at 37 ºC and 5% CO2. 
CT-26 mouse and Caco-2 human colon carcinoma 
cells were maintained in RPMI 1640 DMEM 
medium (MediaTech, Manassas, VA) containing 
10% bovine calf serum, 1 mM sodium pyruvate, 
10 mM HEPES, 2 mM glutamine, penicillin (100 
U/mL) and streptomycin (100 µg/mL), and 2% of 
7.5% w/v NaHCO3 solution. Mouse L1210 
leukemia cells were maintained in RPMI-1640 
medium containing 15% bovine calf serum, 2 mM 
glutamine and 1% MEM amino acids (MediaTech, 
Manassas, VA).  
 
2.3 Mouse Bone Marrow Cells 
Mouse bone marrow cells were obtained from 
female C57BL/6 mice (Jackson Laboratories, Bar 
Harbor, Maine) by flushing the femurs with 3 mL 
of cold medium using a G25 needle. Single cell 
suspension was prepared by passing the cells 
through a G18 needle five times to disperse cell 
cluster and aggregates. The cell mixture was then 
centrifuged at 300 x g (Thermo Electron IEC 
CL31 centrifuge) for 5 min. The medium was 
decanted and the cells were suspended in 5 mL of 
fresh media for counting. 
 
2.4 Synthesis of Compounds 1 - 6 
A schematic representation for the synthesis 
of compounds 1 – 6 is shown in Figure 3. 
 The general procedure for synthesizing these 
compounds is described as follows: To a dry 10 
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mL vial with a stir bar, the appropriate aniline, 
(1.52 mmol) and triethylamine (1.67 mmol) were 
added. The vial was then flushed with argon and 
capped. Under argon, 2.5 mL of dry 
dichloromethane was then added to the vial. 
Finally, the acid chloride (1.52 mmol) was added 
slowly to the vial and the reaction was allowed to 
stir for 3 hours. The reaction was then quenched 
with 3 mL of 5% HCl and washed consecutively 
with saturated NaHCO3 solution, followed by 
brine. The organic and aqueous layers were then 
separated and the aqueous layer was extracted 
three times using 5 mL of dichloromethane. The 
combined organic layers were dried over MgSO4, 
filtered, concentrated, and purified by 
recrystallization using methanol and two drops of 
water (three times).  Excess triethylamine was 
removed under vacuum. Compounds 1 - 5 were 
successfully crystallized using the method 
described above. Compound 6 was purified using 
flash column chromatography with normal phase 




















Figure 3.  Synthetic scheme of the proposed compounds, wherein R1 = Cl and R2 = H or Cl 
 
 
2.5 Disk Diffusion Soft-Agar Colony Formation 
Assay for Cytotoxicity 
A disk diffusion assay was used as a 
screening tool to select  a compound’s activity 
against solid tumors in vitro [11]. Two murine 
neoplasms, colon 38 and L1210 leukemia along 
with one normal cell type (bone marrow 
hematopoietic progenitor) were utilized. In a 
typical assay, 30 g of each compound (15 L of 
2 mg/mL in DMSO) was absorbed on a 6.6 mm 
filter disk (Baxter). After air drying in a laminar 
hood, the disk was placed near the edge of a 60 
mm Petri dish containing established tumor cells 
in a matrix of 0.3% Noble agar (Sigma Chemical, 
St. Louis, MO) with suitable medium. After 7 to 
10 days (per our standard protocol) of incubation, 
a zone of inhibition was measured; the diameter of 
the disk was arbitrarily taken as 200 units and an 
inhibition zone of 1,000 units was defined as total 
killing. If a compound showed a zone of > 300, 
the compound was considered active and was then 
examined against mouse L1210 leukemia cell 
lines for solid tumor selectivity relative to 
leukemia. If the difference in zone between solid 
tumor and the leukemia cells was  250, the 
compound was defined as a “hit” (acceptable solid 
tumor selectivity) and was further examined for 
potential myelotoxicity using normal mouse bone 
marrow cells as the source of hematopoietic 
progenitor cells (CFU-GM assay). For CFU-GM 
assay, an additional 10% L-cell conditioned 
medium was added to culture medium as the 
source of growth factors for the progenitor cells in 
vitro [12]. A significant difference in zones 
between solid tumor cells and normal CFU-GM ( 
250) was defined as a potentially favorable 
therapeutic index (i.e. high ratio of 
efficacy/toxicity)[13].  
 
2.6 IC50 Determination 
The IC50 assay was carried out against mouse 
colon 38 cells and CT-26 colon carcinoma cells. 
Tumor cells were grown in 5 mL of suitable 
culture medium at a starting concentration of 
5x10
4
 cells per T25 flask. On day 3, cells were 
exposed to increasing doses of the test compounds 
(0 – 100 µg/mL). Flasks were incubated for an 
additional 120 hr (5 days) in a 5% CO2 incubator 
at 37 ºC (per our standard protocol) and the cells 
were harvested by trypsinization, washed once 
with HBSS, and re-suspended in an HBSS-trypan 
blue solution. Both total and viable cells were 
counted using a hemocytometer. The results were 
normalized to an untreated control. The IC50 value 
for viable cells was determined using Prism 4.0.  
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2.7 Western Blot Analysis 
After treatment with different concentration 
of compound 3 for 24 hr, colon 38, and Caco2 
cells were collected and lysed in lysis buffer (20 
mM HEPES, pH 7.4, 100 mM NaCl, 1% Nonidet 
P-40, 0.1% SDS, 1% deoxycholic acid, 10% 
glycerol, 1 mM EDTA, 1 mM EGTA, 1 mM 
NaVO3, 50 mM NaF, and cocktail protease 
inhibitors). Soluble proteins were obtained by 
centrifugation at 12,000 x g for 10 min at 4 
o
C and 
protein concentration was measured using a BCA 
protein assay kit. Equal amounts of cell lysate 
were subjected to sodium dodecyl sulfate (SDS)-
polyacrylamide electrophoresis on Novex tris-
glycine pre-cast gels (Invitrogen, Carlsbad, CA) 
and separated proteins were then 
electrotransferred to PVDF membranes [14, 15]. 
After incubation with primary antibodies against 
phospho-STAT3, phospho-Akt, Akt or actin 
overnight at 4 
o
C followed by corresponding 
secondary antibodies, proteins were visualized 
using SuperSignal West Pico chemiluminescence 
substrate system (Pierce, Rockford, IL). The band 
intensity was analyzed using Scion image software 
(Scion Corp., Frederick, MD).  
 
2.8 Flow Cytometric Analysis 
Phosphatidylserine on the plasma membranes 
of colon 38 cells was stained with Annexin V-
FITC (eBioscience, San Diego, CA) according to 
the protocol provided by the manufacturer. 
Briefly, colon 38 cells (5x10
5
/mL) in T25 flasks (5 
mL) were treated with increasing concentrations 
of compound 3 (0, 1, 5 and 10 μg/mL, 
respectively) for 24 hrs. Thereafter, colon cells 
were removed from the flask with trypsin, washed 
with the binding buffer and adjusted to 10
6
/mL. 
Cells (100 µL) were stained with 5 µL Annexin V-
FITC in the dark for 15 min. After staining, cells 
were washed with the binding buffer and 
resuspended in 200 µl binding buffer. Thereafter, 
5 µl of propidium iodide (PI) (100 µg/mL) was 
added to each sample and mixed. Flow cytometric 
analysis was carried out immediately following 
staining with FACScan (Becton Dickinson), and 
data analysis was done on PC-LYSYS v1.1. 
Apoptotic cells were defined as FITC positive and 




3.1 Synthesis  
Identification and characterization of 
compounds 1 - 6 are summarized in Table 1. 
 
3.2 Disk Diffusion Assay  
The criteria for (1) solid tumor selectivity 
relative to leukemia, and (2) in vitro therapeutic 
index are described in the Materials and Methods 
(Disk Diffusion Assay). As shown in Table 2, all 
six compounds showed effective in vitro 
cytotoxicity against colon 38 cells. Four 
compounds (1, 3, 4, and 6) demonstrated solid 
tumor selectivity, but only two compounds (1 and 
3) showed acceptable in vitro therapeutic indices 
(C38ΔCFU >550). 
 
3.3 IC50 Determination 
IC50 values of the six compound synthesized 
are shown in Table 3. Based on the in vitro IC50 
values from both colon-38 and CT-26, compound 
3 was the most potent with solid tumor selectivity. 
Among others, compound 3 also had the lowest 
myelotoxicity as determined by bone marrow 
CFU-GM assay and was selected for further 
biological and mechanistic studies. 
 
3.4 Effect of Compound 3 on Akt Kinase and 
STAT3 
Akt kinase plays an important regulatory role 
in cell proliferation, growth, and survival. 
Overexpression and/or activation of Akt kinase are 
often associated with tumorigenesis and colon 
cancer progression [17-21]. Since mouse colon 38 
cells constitutively express activated Akt kinase, 
we investigated the effect of compound 3 on Akt 
kinase in colon 38 cells. As shown in Figure 4A, 
constitutive expression of phosphorylated Akt 
kinase (p-Akt) was detected in colon 38 cells. 
More than 50% of the Akt kinase of colon 38 cells 
appears to be in phosphorylated states (activated). 
Treatment of colon 38 cells with compound 3 in 
vitro for 24 hr markedly decreased the levels of 
phosphorylated Akt kinase in a dose-dependent 
manner (Figure 4A) with more than two fold 
decrease in phosphorylation at 10 g/mL.  
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Chemical Formula: C10H8N2O2, MW 188 
1
H NMR (400 MHz, CDCl3): Ha,  8.40 (d, 1H, J = 2.8 Hz); Hb,  7.04 (d, 1H, J = 1.6 
Hz); Hc,  8.24 (s (br), 1H); Hd,  7.66 (d, 2H, J = 8.0 Hz); He,  7.40 (t, 2H, J = 7.8 Hz); 
Hf,  7.21 (t, 1H, J = 7.2 Hz) 
HR-MS: EIMS cald for C10H8N2O2 + Na 211.0483, found 211.0478 





















Chemical Formula: C10H7N2O2Cl, MW 222.5 
1H NMR (400 MHz, CDCl3): Ha,  8.42 (d, 1H, J = 1.6 Hz); Hb,  7.06 (d, 1H, J = 1.6 
Hz); Hc,  8.84 (s (br), 1H); HAr,  8.48 (m, 1H),  7.45 (dd, 1H, J = 8.0, 1.6 Hz),  7.34 
(m, 1H),  7.14 (m, 1H) 
HR-MS: EIMS cald for C10H7N2O2Cl + Na 245.0094, found 245.0088 






















Chemical Formula: C10H7N2O2Cl, MW 222.5 
CHN: Cald C H N, found C H N 
1H NMR (400 MHz, CDCl3): Ha,δ 8.40 (d, 1H, J = 1.6 Hz); Hb ,7.05 (d, 1H, J = 1.6 Hz); 
Hc, 8.31 (s (br), 1H); HAr, 7.62 (m, 2H,), 7.40 (m, 2H, Ar)  
13C NMR (100 MHz, CDCl3): δ 151.4, 129.4, 121.4, 107.4 
HRMS: EIMS (M+) calcd for C10H7N2O2Cl + Na 245.0094, found 245.0097 



















Chemical Formula: C10H6N2O2Cl2, MW 257 
1H NMR (400 MHz, CDCl3): Ha,  8.41 (d, 1H J = 2.4); Hb,  7.07 (d, 1H, J = 1.6 Hz); 
Hc,  8.91 (s (br), 1H); HAr,  8.43 (s, 1H),  8.41 (d, 1H, J = 2.4 Hz),  7.28-7.32 (m, 2H) 
HR-MS: EIMS cald for C10H6N2O2Cl2 + Na 278.9704, found 278.9696 




















Chemical Formula: C10H6N2O2Cl2, MW 257 
1H NMR (400 MHz, CDCl3): Ha,  8.42 (d, 1H J = 1.6 Hz); Hb,  7.07 (d, 1H, J = 1.6 
Hz); Hc,  8.78 (s (br), 1H); HAr,  8.44 (d, 1H, J = 8.8 Hz),  7.47 (d, 1H, J = 2.8 Hz),  
7.32 (dd, 1H, J = 8.8, 2 Hz) 

















Chemical Formula: C10H6N2O2Cl2, MW 257 
1H NMR (400 MHz, CDCl3): Ha,  8.41 (d, 1H J = 1.6 Hz); Hb,  7.07 (d, 1H, J = 1.6 
Hz); Hc,  8.17 (s (br), 1H); Hd & Hf,  7.41 (d, 2H, J = 8.0 Hz); He,  7.25 (t, 1H, J = 8.2 
Hz) 
HR-MS: EIMS cald for C10H6N2O2Cl2 + Na 278.9704, found 278.9712 
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               Table 2.  Disk diffusion assay results (zone inhibition) of compounds 1 – 6  
Compound g/disk 
Cells used in Disk-Diffusion Assay Difference in zone unitsc
 
Colon 38 L1210 CFU-GM C38ΔL1210
a C38ΔCFU
b 
1 30 1000 300 550 700 450 
 7.5 500 50 200 450 300 
2 30 350 150 200 200 150 
3 7.5 >1000 200 450 >800 >550 
 1.9 550 50 300 500 250 
4 30 350 100 200 250 150 
5 30 300 100 150 200 150 
6 30 400 150 200 250 150 
a
Solid tumor selectivity relative to leukemia, C38ΔL1210, is the difference in zone units between solid tumor (colon 38 in 
this case) and leukemia L1210.
   b
In vitro toxicity, C38ΔCFU,  is the difference in zone units between solid tumor (colon 
38 in this case) and mouse normal bone marrow CFU-GM. 
c









Colon 38 CT-26 
1 8.6 23 
2 32 ** 
3  2.5*   2.5* 
4 20 26 
5 17 ** 
6 40 ** 
* Meet our criteria of < 5 g/mL   **Not determined 
 
STAT3 is a down stream transcription factor 
for JAK-STAT pathways. Both proteins have been 
shown to be constitutively activated in colorectal 
cancers [22-24]. Like Akt kinase, STAT3 was also 
constitutively active in both mouse colon 38 and 
human colon cancer cells Caco2 as shown by 
strong signal using phosphorylated STAT3 
antibody in control cells (Figure 4B-C). We 
therefore investigated the effect of compound 3 on 
the activation of STAT3 in colon 38 and Caco-2 
cells. Treatment of colon 38 cells with compound 
3 for 24 hr significantly down-regulated 
phosphorylated STAT3 expression in a dose-
dependent manner. While there was more than 
four fold decrease in STAT3 tyrosine 
phosphorylation at 10 µg/mL in colon 38 cells, the 
decrease in STAT3 phosphorylation was more 
prominent in human Caco-2 cells where it 
decreased by more than 10 fold at 80 µg/mL. 
Taken together these results show that compound 
3 was a potent STAT3 inhibitor for both mouse 
and human colon cancer cells. 
 
3.5 Flow Cytometric Analysis of Apoptotic 
Cells 
Since both Akt kinase and STAT3 are 
involved in cell growth and survival, we asked if 
suppression of Akt and STAT3 in colon 38 cells 
may trigger an apoptotic response in colon 38 
cells. Cells were treated with compounds 3 for 24 
hr. Thereafter, cells were removed and subjected 
to flow cytometric analysis after staining with 
FITC-annexin V. There was no significant 
increase of annexin V-binding activity in 
compound 3-treated colon 38 cells (Data not 
shown) as compared to control cultures.  
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Morphological examination showed that colon 38 
cell death appeared to be mediated through 




In this study, we synthesized and examined six 
novel N-(phenyl)-5-carboxamidylisoxazoles for 
their anticancer activity in vitro. In a preliminary 
screening study with the disk-diffusion assay, all 
six compounds were active against mouse colon-
38 cells. However, only two of them (compound 1 
and 3) showed promising in vitro cytotoxicity and 
solid tumor selectivity. Judging from the IC50 
values (2.5 μg/mL) in subsequent studies, 
compound 3 exerts most potent cytotoxic activity 
against both colon-38 and CT-26 mouse colon 
cancer cell lines (Table 3). Furthermore, disk-
diffusion assay revealed that compound 3 was 
highly solid-tumor selective as compared to 
compound 1 (Table 2). Disk-diffusion assay also 
showed that compound 3 exerted a much higher 
cell killing against tumor cell than normal bone 
marrow CFU-GM, suggesting that compound 3 
might have the least myelotoxicity. The molecular 
scaffold used in this work indicates that the 
inductive Cl substitution on the para position of 
phenyl ring appears to be associated with the best 









































Figure 4.  Effect of compound 3 on the activation of 
Akt and STAT. Colon 38 cells were treated with 
increasing doses (0 to 10 µg/mL) of compound 3 for 24 
hr. Cells were then removed, lysed with lysis buffer. 
Equal amounts of lysates were subjected to Western 
blotting using antibodies against phospho-Akt and Akt 
(A), phosphor-STAT3 and STAT3 (B). Human Caco-2 
cells were treated with compound 3 (0-200 µg/mL) for 
24 hr and processed as described in colon 38 cells (C). 
Antibody against actin was used as “house-keeping 
protein.” Densitometric analysis was performed to 
measure the band intensity for each blot. Values are 
means ± S.D. * p < 0.05, ** p < 0.005 vs. medium 
control, n = 3. 
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To further analyze the anti-colon cancer 
activity of compound 3, we carried out a series of 
mechanistic studies on Akt kinase and STAT 
activities in vitro. Overexpression and/or 
activation of Akt kinase have been implicated in 
the tumoregenesis and progression of colorectal 
cancers [17-21]. As expected, treatment of colon 
38 cells in vitro with compound 3 markedly 
deactivated Akt kinase in colon 38 cells as judged 
by the suppressed levels of phosphorylated Akt 
kinase (Figure 4A). The inhibition of Akt kinase 
by compound 3 was dose-dependent, with an IC50 
of approximately 5 g/mL. This value is very 
close to and consistent with that obtained by in 
vitro cytotoxic assay, with an IC50 of 2.5 μg/mL 
(Table 3). Suppression of cancer cell growth and 
induction of apoptosis through Akt signaling 
pathway also have been shown in human 
colorectal cancer cells [20, 21, 25]. These findings 
suggest that targeting Akt pathway is of potential 
in treating patients with colorectal cancers.  
STAT3 has been shown to be constitutively 
activated in some colorectal cancer and is often 
associated with adverse clinical outcome [22-24, 
26, 27]. In recent year, STAT3 has become an 
attractive therapeutic target for various types of 
human cancers with constitutively activated 
STAT3 [23, 28, 29]. STAT3 was constitutively 
phosphorylated (p-STAT3) in both human and 
mouse colon cancer cells (Figure 4B-C). 
Treatment of colon 38 and Caco-2 cells with 
compound 3 readily suppressed the activation of 
STAT3 in a dose-dependent manner. The effective 
concentration for the inhibition of tyrosine 
phosphorylation of STAT3 was lower for mouse 
colon cancer cells as compared to human. The 
differences in the effective concentration could be 
due to variation in the expression level of STAT3 
and associated signaling pathways that lead to 
STAT3 activation in these models of colorectal 
cancer. 
Both Akt kinase and STAT3 are involved in 
cell growth and survival and it has been shown 
that inhibition of Akt and STAT3 can lead to 
apoptosis activation in various cancer cells [20-23, 
27, 28, 30]. Induction of apoptosis in colon 38 
cells by compound 3 was examined by flow 
cytometric analysis with FITC-annexin V. 
Unexpectedly, flow cytometric results showed that 
the cytotoxic effect of compound 3 was not 
mediated through apoptotic pathway. A 
subsequent study using caspase-3 activation 
confirmed that compound 3 did not induce 
apoptosis in colon 38 cells (unpublished 
observation). Judging from morphological 
changes, cell death appears to be mediated through 
non-apoptotic necrosis.   
Compound 3 induces non-apoptotic cell death 
through the inhibition of Akt and STAT3 
signaling pathways both of which are known to be 
constitutively activated in various types of 
colorectal cancer cells. It is not known at present 
whether compound 3 directly interacts with and 
bind to either Akt or STAT3 at protein level. 
Compound 3 may inhibit Akt and STAT3 
indirectly through other metabolic and signaling 
pathways. Of relevance to this study, a recent 
study showed that isoxazole-modified curcumin 
analog derivatives markedly increased its 
antitumor activity including against multidrug 
resistant cells [31]. Still other showed that 
isoxazole carboxylic acid analogs can act as potent 
tyrosine phosphatase inhibitors [32]. At present, it 
is not know whether compound 3 exhibits tyrosine 
phosphatase inhibitory activity. Additional 
mechanistic studies including studies with animal 
tumor modals will be needed to further analyze 
and establish its therapeutic effect against colon 
cancers. Taken together, these studies show that 
isoxazole analogs can form the basis for the 
development of various therapeutic compounds 
against cancer and other diseases. 
 
Abbreviations: CFU-GM, colony forming unit for 
granulocyte and macrophage; DMARD, disease-
modifying anti-rheumatic drug; FITC, fluorescein 
isothiocyanate; JAK3, Janus kinase 3; IC50, half 
maximal inhibitory concentration; PI, propidium 
iodide; STAT3, signal transducer and activator of 
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